Bioequivalence Study of Rivaroxaban 2.5 mg Tablets Under Fasting and Fed Conditions

Inclusion Criteria: * Healthy male or female participant aged 18 years or older. * Body weight at least 50 kg for males or at least 45 kg for females, with body mass index from 19.0 to 26.0 kg/m2, inclusive. * No plan for conception or gamete donation and willing to use effective contraception from screening (from 2 weeks before screening for females) until 6 months after the last dose. * Creatinine clearance greater than 80 mL/min. * Prothrombin time and activated partial thromboplastin time within the normal ranges. * Voluntarily provided written informed consent and understood the study procedures. * Able to comply with and complete the study requirements. Exclusion Criteria: * Specific allergy history, current allergic disease, allergic constitution, or known hypersensitivity to rivaroxaban, related compounds, or formulation components. * Clinically significant abnormal findings on physical examination, vital signs, electrocardiogram, or clinical laboratory testing. * Clinically significant neurologic, cardiovascular, renal, hepatic, gastrointestinal, respiratory, metabolic, musculoskeletal, or other disease that could affect drug absorption, distribution, metabolism, or excretion. * Active pathological bleeding, coagulation abnormality, or clinically relevant bleeding risk. * Positive test for human immunodeficiency virus antibody, hepatitis B surface antigen, hepatitis C antibody, or syphilis antibody. * Hereditary lactose or galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption. * Positive pregnancy test or breastfeeding. * History of drug abuse within 5 years or positive urine drug screen. * Hospitalization or surgery within 3 months before screening. * Regular alcohol intake exceeding 14 units per week within 3 months or positive breath alcohol test. * Smoking more than 5 cigarettes per day on average within 3 months. * Participation in another clinical study with study drug exposure within 3 months. * Blood donation or blood loss of at least 400 mL within 3 months, or donation of 2 therapeutic units of platelets within 1 month. * Use of prescription medication within 14 days, or nonprescription medication, herbal medicine, or health products within 7 days before dosing. * Use within 28 days before first dosing of drugs that strongly inhibit or induce P-glycoprotein or CYP3A4. * Consumption within 48 hours before dosing of grapefruit or related products, alcohol-, caffeine-, or xanthine-containing foods or beverages; strenuous exercise; or other factors potentially affecting pharmacokinetics. * Intolerance of venipuncture or history of needle or blood phobia. * Special dietary requirements or inability to comply with the standardized diet and study restrictions. * Any other condition that could prevent completion of the study or that the investigator considered unsuitable for participation.